Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lanreotide Acetate

FDA-approved product (solution, subcutaneous), marketed as Lanreotide Acetate, Somatuline Depot.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lanreotide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Carcinoid syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Somatostatin and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA68.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lanreotide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lanreotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

    NCT07087054 · start 2025-11-19

    Registered record
    Registry ID
    NCT07087054
    Conditions
    Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor
    Interventions
    Paltusotine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-11-19
    Completion
    2030-01
    Enrolment
    141

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum +5 more
    InterventionPaltusotine; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

    NCT06878664 · start 2025-06-12

    Registered record
    Registry ID
    NCT06878664
    Conditions
    Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
    Interventions
    177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; Amino acid solution; Lanreotide (Autogel formulation) or Octreotide LAR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-06-12
    Completion
    2029-01
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGrade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
    Intervention177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm. +2 more
    PhasePhase 3
    Registry statusRecruiting

  • Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

    NCT05701241 · start 2023-06-28

    Registered record
    Registry ID
    NCT05701241
    Conditions
    Gastroenteropancreatic Neuroendocrine Tumor
    Interventions
    Somatostatin analog
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-06-28
    Completion
    2034-04
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroenteropancreatic Neuroendocrine Tumor
    InterventionSomatostatin analog
    PhasePhase 4
    Registry statusRecruiting

  • Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

    NCT05431803 · start 2022-06-30

    Registered record
    Registry ID
    NCT05431803
    Conditions
    Acromegaly
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-06-30
    Completion
    2024-12-13
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

    NCT05364944 · start 2022-05-18

    Registered record
    Registry ID
    NCT05364944
    Conditions
    Acromegaly; GEP-NET
    Interventions
    Debio 4126; Sandostatin LAR; Somatuline ATG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-05-18
    Completion
    2024-12-03
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly; GEP-NET
    InterventionDebio 4126; Sandostatin LAR; Somatuline ATG
    PhasePhase 1
    Registry statusTerminated

  • Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    NCT05477576 · start 2022-03-24

    Registered record
    Registry ID
    NCT05477576
    Conditions
    GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET
    Interventions
    RYZ101; Everolimus; Sunitinib; Octreotide; Lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-03-24
    Completion
    2030-12
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors +3 more
    InterventionRYZ101; Everolimus; Sunitinib; Octreotide +1 more
    PhasePhase 3
    Registry statusRecruiting

  • Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

    NCT05048901 · start 2021-09-17

    Registered record
    Registry ID
    NCT05048901
    Conditions
    Neuroendocrine Tumors,Gastroenteropancreatic
    Interventions
    Cabozantinib; Lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2021-09-17
    Completion
    2027-12-31
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors,Gastroenteropancreatic
    InterventionCabozantinib; Lanreotide
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

    NCT04696042 · start 2021-01-01

    Registered record
    Registry ID
    NCT04696042
    Conditions
    Neuroendocrine Tumors
    Interventions
    Lanreotide autogel
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2025-01-27
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors
    InterventionLanreotide autogel
    PhaseNot recorded
    Registry statusCompleted

  • Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.

    NCT03947762 · start 2019-07-03

    Registered record
    Registry ID
    NCT03947762
    Conditions
    Pancreatic Neuroendocrine Tumor
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2019-07-03
    Completion
    2021-04-30
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Neuroendocrine Tumor
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma

    NCT03439709 · start 2018-03-01

    Registered record
    Registry ID
    NCT03439709
    Conditions
    Acromegaly Due to Pituitary Adenoma
    Interventions
    Gamma knife radiosurgery; Lanreotide 60Mg Solution for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-03-01
    Completion
    2022-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly Due to Pituitary Adenoma
    InterventionGamma knife radiosurgery; Lanreotide 60Mg Solution for Injection
    PhasePhase 3
    Registry statusUnknown

  • A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

    NCT03174353 · start 2018-02-20

    Registered record
    Registry ID
    NCT03174353
    Conditions
    Pancreatic Leak; Pancreatic Fistula; Pancreaticoduodenal; Fistula; Pancreatectomy; Hyperglycemia
    Interventions
    Lanreotide Prefilled Syringe
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-02-20
    Completion
    2021-04-01
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Leak; Pancreatic Fistula; Pancreaticoduodenal; Fistula +2 more
    InterventionLanreotide Prefilled Syringe
    PhasePhase 2
    Registry statusCompleted

  • The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

    NCT03158090 · start 2017-12-15

    Registered record
    Registry ID
    NCT03158090
    Conditions
    Acromegaly
    Interventions
    Transnasal butterfly surgery; sandostatin; radiotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2017-12-15
    Completion
    2051-01-30
    Enrolment
    1,965

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionTransnasal butterfly surgery; sandostatin; radiotherapy
    PhaseNot recorded
    Registry statusRecruiting

  • Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

    NCT03083210 · start 2017-07-05

    Registered record
    Registry ID
    NCT03083210
    Conditions
    Neuroendocrine Tumors
    Interventions
    Lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-07-05
    Completion
    2020-02
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors
    InterventionLanreotide
    PhasePhase 4
    Registry statusUnknown

  • Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

    NCT03043664 · start 2017-07-01

    Registered record
    Registry ID
    NCT03043664
    Conditions
    Gastroenteropancreatic Neuroendocrine Tumors
    Interventions
    Lanreotide; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-07-01
    Completion
    2022-06-07
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroenteropancreatic Neuroendocrine Tumors
    InterventionLanreotide; Pembrolizumab
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

    NCT02683941 · start 2017-03-06

    Registered record
    Registry ID
    NCT02683941
    Conditions
    Neuroendocrine Tumors in Lung
    Interventions
    Lanreotide (Autogel formulation); Placebo; Best Supportive Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-03-06
    Completion
    2020-02-28
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors in Lung
    InterventionLanreotide (Autogel formulation); Placebo; Best Supportive Care
    PhasePhase 3
    Registry statusTerminated